Harnessing preclinical mouse models to inform human clinical cancer trials

被引：40

作者：

Gutmann, DH

Hunter-Schaedle, K

Shannon, KM

机构：

[1] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA

[2] Childrens Tumor Fdn, New York, NY USA

[3] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2006年 / 116卷 / 04期

关键词：

D O I：

10.1172/JCI28271

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The urgent need for better cancer treatments has stimulated interest in employing small-animal models to evaluate potential drug therapies. Robust mouse models of many human cancers have been generated using sophisticated technologies for engineering germ-line mutations. As we enter into an age of targeted therapeutics, these strains provide novel platforms for validating new anticancer drugs, assessing therapeutic index, identifying surrogate markers of tumor progression, and defining epigenetic and environmental influences on tumorigenesis.

引用

页码：847 / 852

页数：6

共 96 条

[1]

Abate-Shen Cory, 2002, Trends Genet, V18, pS1, DOI 10.1016/S0168-9525(02)02683-5

[2]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[3] A mouse model recapitulating molecular features of human mesothelioma [J].

Altomare, DA ;

Vaslet, CA ;

Skele, KL ;

De Rienzo, A ;

Devarajan, K ;

Jhanwar, SC ;

McClatchey, AI ;

Kane, AB ;

Testa, JR .

CANCER RESEARCH, 2005, 65 (18) :8090-8095

[4] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[5]

Bajenaru ML, 2003, CANCER RES, V63, P8573

[6] TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia [J].

Bhowmick, NA ;

Chytil, A ;

Plieth, D ;

Gorska, AE ;

Dumont, N ;

Shappell, S ;

Washington, MK ;

Neilson, EG ;

Moses, HL .

SCIENCE, 2004, 303 (5659) :848-851

[7] Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells [J].

Bollag, G ;

Clapp, DW ;

Shih, S ;

Adler, F ;

Zhang, YY ;

Thompson, P ;

Lange, BJ ;

Freedman, MH ;

McCormick, F ;

Jacks, T ;

Shannon, K .

NATURE GENETICS, 1996, 12 (02) :144-148

[8] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].

Carter, TA ;

Wodicka, LM ;

Shah, NP ;

Velasco, AM ;

Fabian, MA ;

Treiber, DK ;

Milanov, ZV ;

Atteridge, CE ;

Biggs, WH ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Mehta, SA ;

Patel, HK ;

Pao, W ;

Sawyers, CL ;

Varmus, H ;

Zarrinkar, PP ;

Lockhart, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016

[9] Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease [J].

Chan, IT ;

Kutok, JL ;

Williams, IR ;

Cohen, S ;

Kelly, L ;

Shigematsu, H ;

Johnson, L ;

Akashi, K ;

Tuveson, DA ;

Jacks, T ;

Gilliland, DG .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (04) :528-538

[10] Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors [J].

Chenevert, TL ;

Stegman, LD ;

Taylor, JMG ;

Robertson, PL ;

Greenberg, HS ;

Rehemtulla, A ;

Ross, BD .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (24) :2029-2036

← 1 2 3 4 5 6 7 8 9 10 →